Loading...
Loading...
Contributors:
Dataset URI:
10.6084/m9.figshare.34329832.v1Stroke-heart syndrome (SHS) is associated with poor outcomes after ischemic stroke (IS), but the relationship between dexmedetomidine (DEX) use and SHS remains unclear. To evaluate the association between DEX use and SHS in critically ill patients with IS. This retrospective cohort study used MIMIC-IV v2.2. Patients with IS receiving mechanical ventilation were included. DEX exposure was defined as use within 72 hours after ICU admission. Multivariate logistic regression, inverse probability of treatment weighting (IPTW), restricted cubic splines, and subgroup analyses were performed. Among 953 patients, 146 (15.3%) received DEX. In the fully adjusted model, DEX use was associated with lower odds of SHS (OR = 0.611, 95% CI: 0.398–0.929, p = 0.023). The associations of cumulative DEX dose (p-nonlinearity = 0.018) and treatment duration (p-anonlinearity = 0.011) with SHS were nonlinear. Antiplatelet therapy significantly modified the DEX-SHS association (p-interaction = 0.042). DEX use was associated with lower odds of SHS in critically ill patients with IS. Antiplatelet therapy may modify this association. Prospective studies are needed to confirm these findings.
Keyword(s):
Cancer; Cell Biology; critical care; dexmedetomidine; Infectious Diseases.
MeSH Term(s):
Grants and Funding:
No Grants or Funding Data Available
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)